MX2012001916A - Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos. - Google Patents
Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.Info
- Publication number
- MX2012001916A MX2012001916A MX2012001916A MX2012001916A MX2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A
- Authority
- MX
- Mexico
- Prior art keywords
- red blood
- blood cell
- cell levels
- erythropoietin receptor
- receptor activators
- Prior art date
Links
- 108010075944 Erythropoietin Receptors Proteins 0.000 title abstract 2
- 102100036509 Erythropoietin receptor Human genes 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- 210000003743 erythrocyte Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010059616 Activins Proteins 0.000 abstract 1
- 102000005606 Activins Human genes 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000000488 activin Substances 0.000 abstract 1
- 108010023079 activin B Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/583,177 US8058229B2 (en) | 2008-08-14 | 2009-08-13 | Method of increasing red blood cell levels or treating anemia in a patient |
| PCT/US2009/004659 WO2010019261A1 (en) | 2008-08-14 | 2009-08-13 | Use of gdf traps to increase red blood cell levels |
| US30590110P | 2010-02-18 | 2010-02-18 | |
| PCT/US2010/045509 WO2011020045A1 (en) | 2009-08-13 | 2010-08-13 | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012001916A true MX2012001916A (es) | 2012-05-22 |
Family
ID=43586530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001916A MX2012001916A (es) | 2009-08-13 | 2010-08-13 | Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos. |
| MX2019010341A MX2019010341A (es) | 2009-08-13 | 2012-02-13 | Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010341A MX2019010341A (es) | 2009-08-13 | 2012-02-13 | Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos. |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP3838919A1 (enExample) |
| JP (4) | JP5909446B2 (enExample) |
| KR (5) | KR102170682B1 (enExample) |
| CN (7) | CN105535938B (enExample) |
| AU (1) | AU2010282361B2 (enExample) |
| BR (2) | BR112012003232B1 (enExample) |
| CA (1) | CA2770822C (enExample) |
| ES (2) | ES2844123T3 (enExample) |
| IL (6) | IL287990B (enExample) |
| MX (2) | MX2012001916A (enExample) |
| NZ (3) | NZ598348A (enExample) |
| RU (2) | RU2592670C2 (enExample) |
| WO (1) | WO2011020045A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| DK3520805T3 (da) * | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| CA2889209C (en) * | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| JP2017509647A (ja) * | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| AU2015339134B2 (en) * | 2014-10-30 | 2021-06-17 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| WO2016128523A1 (en) * | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| EP3298034A4 (en) * | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| JP7072507B2 (ja) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | 眼の障害を処置するための方法 |
| KR20180128405A (ko) * | 2016-02-22 | 2018-12-03 | 악셀레론 파마 인코포레이티드 | 면역 활성 증가에 사용하기 위한 ActRII 길항제 |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| LT3490582T (lt) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| WO2018067740A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma, Inc. | Compositions and method for treating kidney disease |
| AU2017338916B2 (en) * | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2018231905A1 (en) | 2017-06-14 | 2018-12-20 | Celgene Corporation | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| IL278546B2 (en) * | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| US12310982B2 (en) | 2018-12-10 | 2025-05-27 | Elena Valentinovna ARSHINTSEVA | Use of the poloxamer as a pharmacologically active substance |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN111466337B (zh) * | 2020-05-19 | 2022-04-19 | 山东大学齐鲁医院 | 一种腹主动脉瘤动物模型及其构建方法 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN115317589B (zh) * | 2022-09-05 | 2024-12-13 | 中国海洋大学 | 脯氨酰羟化酶抑制剂及其应用 |
| CN119198238A (zh) * | 2024-09-18 | 2024-12-27 | 广东省安家医健健康管理有限公司 | 一种地中海贫血检测系统及试剂盒 |
| CN122404564A (zh) * | 2025-01-15 | 2026-07-17 | 沈阳三生制药有限责任公司 | 一种ActRⅡB融合蛋白及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| EP0830459B1 (en) | 1995-04-11 | 2007-01-24 | The General Hospital Corporation | Reverse two-hybrid systems |
| JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
| MEP90708A (hr) * | 2000-05-15 | 2011-12-20 | Nova farmaceutska smješa | |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| HU229475B1 (en) * | 2001-12-06 | 2014-01-28 | Fibrogen | Methods of increasing endogenous erythropoietin (epo) |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| BRPI0407276A (pt) * | 2003-02-07 | 2006-01-31 | Prometic Biosciences Inc | ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese |
| GB0304424D0 (en) * | 2003-02-26 | 2003-04-02 | Glaxosmithkline Biolog Sa | Novel compounds |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| BRPI0518728A2 (pt) * | 2004-12-09 | 2008-12-02 | Univ Pittsburgh | vacinas para a resposta rÁpida À pandemia de gripe aviÁria |
| JPWO2006115274A1 (ja) * | 2005-04-26 | 2008-12-18 | 味の素株式会社 | 骨髄赤血球前駆細胞分化促進剤 |
| EP1934246B8 (en) * | 2005-10-07 | 2012-02-08 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Matrix metalloproteinase 11 vaccine |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008073292A2 (en) * | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| CA2672758C (en) * | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TW201627320A (zh) * | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| DK3750552T5 (da) * | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
-
2010
- 2010-08-13 KR KR1020197027722A patent/KR102170682B1/ko active Active
- 2010-08-13 ES ES16186033T patent/ES2844123T3/es active Active
- 2010-08-13 CN CN201510979490.9A patent/CN105535938B/zh active Active
- 2010-08-13 NZ NZ598348A patent/NZ598348A/en unknown
- 2010-08-13 ES ES10808838T patent/ES2796121T3/es active Active
- 2010-08-13 BR BR112012003232-1A patent/BR112012003232B1/pt active IP Right Grant
- 2010-08-13 IL IL287990A patent/IL287990B/en unknown
- 2010-08-13 AU AU2010282361A patent/AU2010282361B2/en active Active
- 2010-08-13 WO PCT/US2010/045509 patent/WO2011020045A1/en not_active Ceased
- 2010-08-13 KR KR1020227045338A patent/KR102606494B1/ko active Active
- 2010-08-13 CN CN202110421547.9A patent/CN113171442B/zh active Active
- 2010-08-13 NZ NZ623113A patent/NZ623113A/en unknown
- 2010-08-13 EP EP20197940.8A patent/EP3838919A1/en not_active Withdrawn
- 2010-08-13 CN CN201080045618.XA patent/CN102655872B/zh active Active
- 2010-08-13 CN CN201510979350.1A patent/CN105561295B/zh active Active
- 2010-08-13 KR KR1020187020803A patent/KR20180085825A/ko not_active Ceased
- 2010-08-13 CA CA2770822A patent/CA2770822C/en active Active
- 2010-08-13 EP EP16186033.3A patent/EP3117829B1/en active Active
- 2010-08-13 RU RU2012109393/10A patent/RU2592670C2/ru active
- 2010-08-13 JP JP2012524910A patent/JP5909446B2/ja active Active
- 2010-08-13 KR KR1020127004678A patent/KR101882521B1/ko active Active
- 2010-08-13 CN CN201510979291.8A patent/CN105412908B/zh active Active
- 2010-08-13 CN CN202110417494.3A patent/CN113082194B/zh active Active
- 2010-08-13 KR KR1020207030283A patent/KR20200124322A/ko not_active Ceased
- 2010-08-13 MX MX2012001916A patent/MX2012001916A/es active IP Right Grant
- 2010-08-13 CN CN202110879546.9A patent/CN113577291A/zh active Pending
- 2010-08-13 RU RU2016123808A patent/RU2642302C1/ru active
- 2010-08-13 EP EP10808838.6A patent/EP2464369B1/en active Active
- 2010-08-13 BR BR122020019169-4A patent/BR122020019169B1/pt active IP Right Grant
- 2010-08-13 NZ NZ712943A patent/NZ712943A/en unknown
-
2012
- 2012-02-12 IL IL218052A patent/IL218052A/en active IP Right Grant
- 2012-02-13 MX MX2019010341A patent/MX2019010341A/es unknown
-
2015
- 2015-12-03 JP JP2015236828A patent/JP2016034981A/ja not_active Withdrawn
-
2017
- 2017-05-01 IL IL252046A patent/IL252046B/en active IP Right Grant
- 2017-05-01 IL IL252045A patent/IL252045B/en active IP Right Grant
- 2017-05-01 IL IL25204417A patent/IL252044B/en active IP Right Grant
-
2018
- 2018-08-17 JP JP2018153528A patent/JP6860533B2/ja active Active
-
2020
- 2020-07-05 IL IL275851A patent/IL275851B/en unknown
- 2020-09-29 JP JP2020163806A patent/JP2020203953A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010341A (es) | Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos. | |
| MX336846B (es) | Alteracion genomica dirigida. | |
| CL2011002857A1 (es) | Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares. | |
| CL2014003168A1 (es) | Compuestos derivados de tetrahidrofurano o tetrahidrotiofeno teniendo un resto d-aminoacido; composicion farmaceutica que los comprende, util para el tratamiento de un huesped infectado con el virus de la hepatitis c. | |
| EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
| EA201190013A1 (ru) | Ингибиторы ns5a вгс | |
| CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| CL2014000612A1 (es) | Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc). | |
| CL2015001724A1 (es) | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. | |
| EA201590887A1 (ru) | Композиция | |
| CL2016001580A1 (es) | Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación. | |
| PE20151775A1 (es) | Polipeptidos de fenilalanina amoniaco liasa modificados por ingenieria genetica | |
| PH12014502697B1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| CL2009000639A1 (es) | Pirimidinas-5-acarboxamidas sustituidas; la composicion farmceutica que la contiene; y sus usos. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| EA201391637A1 (ru) | Ингибиторы вируса гепатита c | |
| ECSP15011603A (es) | Subunidades de vacunas de inmersión para peces | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| BR112015012841A2 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| AR099500A1 (es) | Composición para el desmucilaginado enzimático de aceite | |
| EA201490846A1 (ru) | Новые производные арилхинолина | |
| CL2012000583A1 (es) | Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras. | |
| CL2008003095A1 (es) | Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario. | |
| CL2011000262A1 (es) | Virus de bronquitis infecciosa (bi) derivado de un virus similar a qx-bi; composicion de vacuna que comprende dicho virus; procedimiento para preparar dicho virus. | |
| EA201590770A1 (ru) | Ингибиторы вируса гепатита с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |